The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia

Leuk Lymphoma. 2010 May;51(5):941-3. doi: 10.3109/10428191003682783.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Colonic Diseases / chemically induced
  • Colonic Diseases / drug therapy*
  • Dasatinib
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Methylprednisolone / therapeutic use*
  • Pleural Effusion / chemically induced
  • Pleural Effusion / drug therapy*
  • Prognosis
  • Protein Kinase Inhibitors / adverse effects
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / adverse effects*
  • Subcutaneous Tissue / drug effects*
  • Subcutaneous Tissue / pathology
  • Thiazoles / adverse effects*
  • Thymosin / therapeutic use*
  • Treatment Outcome
  • Ulcer / chemically induced
  • Ulcer / drug therapy*

Substances

  • Anti-Inflammatory Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Thymosin
  • Protein-Tyrosine Kinases
  • Dasatinib
  • Methylprednisolone